Immunoglobulin heavy variable 3 family B-cell receptor (VH3+ BCR) (VH3+ BCR)

The Immunoglobulin heavy variable 3 family B-cell receptor (VH3+ BCR) is a membrane-bound immunoglobulin complex that incorporates the IGHV3 gene family, the largest and most diverse heavy chain variable region family in humans [IMGT, 2023]. These receptors are vital for the adaptive immune system, as they facilitate the recognition of a broad spectrum of antigens and initiate signaling pathways required for B-cell activation, proliferation, and survival [Nature Reviews Immunology, 2017]. In clinical oncology, the expression of specific VH3 genes, particularly IGHV3-21, is a well-established biomarker for poor prognosis in Chronic Lymphocytic Leukemia (CLL), identifying patients likely to experience more aggressive disease courses [Blood, 2002]. A unique structural feature of VH3+ BCRs is their ability to bind B-cell superantigens, such as Staphylococcal Protein A, which interact with the conserved framework regions of the VH3 domain rather than the conventional antigen-binding site [PNAS, 2000]. Therapeutic management of diseases involving these receptors typically focuses on inhibiting the B-cell receptor signaling axis using Bruton's tyrosine kinase (BTK) inhibitors like Ibrutinib or phosphoinositide 3-kinase (PI3K) inhibitors like Idelalisib [New England Journal of Medicine, 2013]. Additionally, monoclonal antibodies such as Rituximab are employed to deplete the B-cell populations expressing these receptors in both malignant and autoimmune contexts [Lancet, 2004]. The study of VH3+ BCRs continues to inform the development of targeted therapies and personalized diagnostic strategies in hematology and immunology [Journal of Clinical Oncology, 2015].

Other names

IGHV3-positive B-cell receptorVH3-encoded B-cell receptorImmunoglobulin heavy chain variable 3 familyIGHV3 BCRVH3-family B-cell receptor

The mechanism of action for drugs addressing VH3+ B-cell receptors primarily involves the inhibition of intracellular signaling components such as Bruton's tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3K), which are essential for the survival of B-cells expressing these receptors [NEJM, 2013; Lancet Oncology, 2014]. Monoclonal antibodies like Rituximab and Obinutuzumab target surface antigens (e.g., CD20) to induce B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [Lancet, 2004]. Furthermore, the VH3 framework region serves as a binding site for B-cell superantigens like Staphylococcal Protein A, which can be used in experimental settings to modulate B-cell activity or induce apoptosis [PNAS, 2000].